Back to top
more

Geron (GERN)

(Real Time Quote from BATS)

$4.00 USD

4.00
8,066,917

-0.14 (-3.38%)

Updated Apr 30, 2024 02:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study

by Zacks Equity Research

Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.

Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies

by Zacks Equity Research

Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.

Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints

by Zacks Equity Research

Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.

Novartis (NVS) Announces Positive Data on Oncology Drug

by Zacks Equity Research

Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.

Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma

by Zacks Equity Research

Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.

Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA

by Zacks Equity Research

Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.

Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation

by Zacks Equity Research

Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.

Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion

by Zacks Equity Research

Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.

Radius (RDUS) to Go Private With $890M Deal, Shares Gain

by Zacks Equity Research

Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.

Gilead (GILD) Announces Positive Data on Hepcludex for HDV

by Zacks Equity Research

Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.

Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug

by Zacks Equity Research

Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.

Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion

by Zacks Equity Research

Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.

Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies

by Zacks Equity Research

Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.

Bausch (BHC) Suspends IPO Plans for Solta Medical

by Zacks Equity Research

Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.

Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints

by Zacks Equity Research

Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.

Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe

by Zacks Equity Research

Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.

Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug

by Zacks Equity Research

Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.

Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health

by Zacks Equity Research

Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

by Zacks Equity Research

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.

Has Geron (GERN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Geron (GERN) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks

by Zacks Equity Research

Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.

Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib

by Zacks Equity Research

Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.

Radius (RDUS) to Stop Work on Abaloparatide Transdermal System

by Zacks Equity Research

Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.

Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah

by Zacks Equity Research

Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.

Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC

by Zacks Equity Research

Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.